Wolverine

The nickname is a marketing label, not a formulation. Where amounts are stated they are specific to that seller's vial, so this profile intentionally records no universal composition.

• BPC-157 — read the evidence profile
• TB-500 — read the evidence profile

  Material sold as TB-500 may be a thymosin beta-4 fragment rather than full thymosin beta-4. Studies of one do not automatically apply to the other, so the ingredient itself is not a fixed quantity.

Blends are mixtures sold under a nickname. The name is chosen by whoever is selling it, so two vials with the same name can contain different ingredients in different amounts. Any evidence level shown here describes the combined marketed mixture, which is almost always untested as a mixture.

• No blend-specific controlled human evidence identified in the curated record.

BPC-157's healing story rests largely on rodent work, and thymosin beta-4 material has no dependable controlled human trials for tendon or soft-tissue repair. Combining two ingredients with weak human evidence produces a mixture with weak human evidence, not a stronger one.

The name says nothing about which peptide material was used, how much of each is present, or whether the mixture matches its label.

• Whether the TB-500 component is full thymosin beta-4 or a fragment.
• The proportion of each ingredient, which varies between formulations.
• Stability and sterility of the two peptides combined in one vial.
• Whether either ingredient reaches the injured tissue in a meaningful way in humans.

Neither ingredient is an approved medicine for tissue repair, and the mixture is not an approved product anywhere. Unapproved status means nobody has vetted identity, purity or safety — not that the mixture has been shown to be dangerous.

• No controlled human safety data for the combination.
• No long-term follow-up in people using it for injuries.
• Contamination and mislabelling risk from unregulated injectable supply.